Michelle Mojadidi

Michelle Mojadidi is a scientist at Neogene Therapeutics, a biotechnology company specializing in engineered T cell receptor (TCR) therapies targeting solid tumors. She has a strong background in biotechnology and biomedical research, as indicated by her experience and education, including studies at the University of California.34

At Neogene Therapeutics, Mojadidi contributes to the development of next-generation therapies that utilize neoantigen-targeting TCRs to attack cancer cells. This approach aims to provide personalized treatment options for patients with various types of solid cancers by leveraging the unique genetic mutations present in their tumors.12

Mojadidi has been involved in significant research efforts, including non-clinical evaluations of autologous T cell products aimed at treating specific cancer mutations.45 Her work reflects a commitment to advancing innovative cancer therapies and improving patient outcomes in oncology.